Zobrazeno 1 - 10
of 3 723
pro vyhledávání: ''
Autor:
Anna Wall, Herve Ghesquieres, Viola Poeschel, Jesse G. Dixon, Hervé Tilly, Marita Ziepert, Amy S. Ruppert, Qian Shi, David Cunningham, Norbert Schmitz, Christopher R. Flowers, Corinne Haioun, Jocelyne Flament, Gilles Salles
Great heterogeneity in survival exists for patients newly diagnosed with diffuse large B-cell lymphoma (DLBCL). Three scoring systems incorporating simple clinical parameters (age, lactate dehydrogenase, number/sites of involvement, stage, performanc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::86b84f2887e4b5caa58b54159bae05ed
Pembrolizumab for B-cell lymphomas relapsing after or refractory to CD19-directed CAR T-cell therapy
Autor:
Simon F. Lacey, Stephen J. Schuster, Elise A. Chong, Sunita D. Nasta, Jakub Svoboda, Marco Ruella, Siddharth Bhattacharyya, E. John Wherry, Cécile Alanio, Daniel J. Landsburg
Publikováno v:
Blood
CD19-directed chimeric antigen receptor–modified (CAR T) T cells achieve durable remissions in about 30% to 40% of relapsed/refractory large B-cell lymphomas. T-cell exhaustion and/or an immunosuppressive tumor microenvironment may contribute to CA
Autor:
Jeff P. Sharman, Peter Trask, Yeung-Chul Mun, Anthony Masaquel, Habte A. Yimer, Alexey V. Danilov, John M. Burke, Sunil Babu, Jia Li, Michael Boxer
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 22:121-128
Introduction: Longitudinal changes in health-related quality of life (HRQoL) are important in patients with chronic lymphocytic leukemia (CLL). GIBB (NCT02320487) is an open-label, single-arm phase II study of obinutuzumab (GA101; G) in combination w
Autor:
Stephen S. Rich, Donna Neuberg, Michael H. Cho, Bing Yu, Matthew Leventhal, George T. O'Connor, Ani Manichaikul, Weiwei Shi, Lynette M. Sholl, Michael C. Honigberg, Abhishek Niroula, Benjamin L. Ebert, Joselyn Rojas-Quintero, R. Graham Barr, Matthew Moll, Stephanie J. London, L. Adrienne Cupples, Siddhartha Jaiswal, Elizabeth C. Oelsner, Brittany E Sandoval, Pradeep Natarajan, Brian E. Cade, Peter van Galen, Susan Redline, Yohannes Tesfaigzi, Christopher J. Gibson, Stephanie M. Gogarten, COPDGene Study Investigators, Deepti Jain, Adolfo Correa, Bruce D. Levy, Sina A. Gharib, Peter Miller, Kaushik Viswanathan, Caroline A. Owen, Edwin K. Silverman, Lillian Werner, Jerome I. Rotter, Dandi Qiao, Brian C. Miller, Adam S. Sperling, Leslie A. Lange, Alexander G. Bick, Marie McConkey, Vasan S. Ramachandran
Publikováno v:
Blood. 139:357-368
Chronic obstructive pulmonary disease (COPD) is associated with age and smoking, but other determinants of the disease are incompletely understood. Clonal hematopoiesis of indeterminate potential (CHIP) is a common, age-related state in which somatic
Autor:
Christoph Schliemann, Sylvia Herold, Friedrich Stölzel, Claudia D. Baldus, Sebastian Scholl, Richard Noppeney, Michael Kramer, Martin Bornhäuser, Martin Kaufmann, Julia Annabell Georgi, Tim H. Brümmendorf, Uwe Platzbecker, Hubert Serve, Carsten Müller-Tidow, Bjoern Steffen, Wolfgang E. Berdel, Stefan W. Krause, Sebastian Stasik, Malte von Bonin, Ralph Naumann, Andreas Petzold, Kerstin Schäfer-Eckart, Andreas Neubauer, Gerhard Ehninger, Mathias Hänel, Alwin Krämer, Roger Mulet-Lazaro, Hermann Einsele, Utz Krug, Markus Schaich, Andreas Hochhaus, Johannes Schetelig, Peter J. M. Valk, Christian Thiede, Christoph Röllig, Andreas Burchert, Franziska Taube, Jan Moritz Middeke, Katja Sockel, Ulrich Kaiser
Publikováno v:
Blood, 139(1), 87-103. American Society of Hematology
Biallelic mutations of the CEBPA gene (CEBPAbi) define a distinct entity associated with favorable prognosis; however, the role of monoallelic mutations (CEBPAsm) is poorly understood. We retrospectively analyzed 4708 adults with acute myeloid leukem
Autor:
Seema A. Bhat, Adam Kittai, Kyle A. Beckwith, Cecelia R. Miller, Ying Huang, Daniel Goldstein, Jennifer A. Woyach, Kerry A. Rogers, Lynne V. Abruzzo, Amy S. Ruppert, Michael R. Grever, John C. Byrd, David A. Bond, Nyla A. Heerema
Publikováno v:
Blood. 138:2372-2382
Complex karyotype, defined as ≥3 cytogenetic abnormalities, is prognostic of survival in patients treated with ibrutinib or venetoclax in relapsed/refractory (RR) chronic lymphocytic leukemia (CLL). Recent studies re-evaluating this dichotomous var
Publikováno v:
Oxidative Medicine and Cellular Longevity
Oxidative Medicine and Cellular Longevity, Vol 2021 (2021)
Oxidative Medicine and Cellular Longevity, Vol 2021 (2021)
Objective. Galectin-3, an inflammatory mediator derived from microglia, participates in the pathophysiological process of various neurological diseases. However, the relationship between galectin-3 and poststroke cognitive impairment (PSCI) remains a
Publikováno v:
Biochemical and Biophysical Research Communications. 584:60-65
Current study is intended to evaluate the expression and epigenetic variations of mitochondrial situins in 306 rheumatoid arthritis (RA) cases and compared with age/gender matched controls.The expression level was measured using the quantitative Real
Autor:
Philipp le Coutre, Véronique Bédoucha, Delphine Rea, Dennis Dong Hwan Kim, Elza Lomaia, Michael J. Mauro, Andre Abdo, Lynette Chee, Sergey Voloshin, Dong-Wook Kim, Laura Fogliatto, Paola Aimone, Yosuke Minami, Alex Allepuz, Mario Annunziata, Jane F. Apperley, Susanne Saussele, Jorge E. Cortes, Andreas Hochhaus, Naeem Chaudhri, Carla Boquimpani, Koji Sasaki, Sara Quenet, Timothy P. Hughes, Anna G. Turkina, Valentín García-Gutiérrez
Publikováno v:
Blood
Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to ≥2 tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of disease biology and inadequate efficacy and/or safety of current
Autor:
Philomena Colucci, Jingbo Yu, Jonathan Kish, Dilan Paranagama, Shreekant Parasuraman, Kevin C Lord, Ivy Altomare
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 21:e915-e921
Background Polycythemia vera (PV) is a myeloproliferative neoplasm affecting >100,000 people in the United States annually. Patients (pts) with PV are at risk for thromboembolic events (TEs), premature death, and high symptom burden. Hydroxyurea (HU)